Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389216 | 0.90 | GAA (0.52) | HPGDHDAC3HDAC1SMN1; SMN2HDAC2 | |
| SCHEMBL4483167 | 0.85 | HPGD (0.61) | HPGDRAB9AKMT2AHDAC3HDAC1 | |
| SCHEMBL6385728 | 0.82 | ACKR3 (0.53) | HPGDKMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL6384340 | 0.81 | HDAC3 (0.49) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6385892 | 0.81 | ACKR3 (0.54) | RAB9AKMT2AHDAC3HDAC1TP53 | |
| SCHEMBL6762618 | 0.81 | HDAC1 (0.48) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6383652 | 0.79 | HDAC1 (0.48) | HPGDHTTRAB9APOLBKMT2A | |
| SCHEMBL6384887 | 0.79 | MAPK1 (0.56) | HPGDHTTHDAC3HDAC1HDAC2 | |
| SCHEMBL6076439 | 0.76 | HDAC1 (0.60) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6759168 | 0.76 | LMNA (0.47) | HPGDKMT2AHDAC3HDAC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC11, HDAC10 | HPGD 1098/4885HTT 2099/4885RAB9A 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.